Form 4: Sage Therapeutics Director James Frates Granted 21,500 Stock Options Under 2024 Equity Plan

Sage Therapeutics, Inc. Director James M. Frates was granted 21,500 stock options with an exercise price of $6.77, vesting by June 2026, as part of the company's 2024 Equity Incentive Plan.

Summary

• Director James M. Frates acquired 21,500 stock options in Sage Therapeutics, Inc. on June 11, 2025.
• The stock options have an exercise price of $6.77 per share and will expire on June 11, 2035.
• The options were issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan and the Non-Employee Director Compensation Program.
• Vesting for these options will occur in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard and generally positive event, aligning management/director interests with shareholders.

Positives

• The grant of 21,500 stock options to Director James M. Frates aligns his interests with those of shareholders, incentivizing long-term value creation.
• The options were issued under the company's 2024 Equity Incentive Plan, indicating a structured and approved approach to executive and director compensation.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continued service from Director James M. Frates until at least June 2026 or the 2026 Annual Meeting, aligning his long-term commitment with the company's future performance.

Management Comments

• "The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program."
• "The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."

Industry Context

The granting of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industry, aligning director incentives with long-term shareholder value and promoting retention. This aligns with typical corporate governance structures for publicly traded companies.

Comparison to Industry Standards

• The compensation structure, involving stock options for non-employee directors, is consistent with common practices observed across the biotechnology and pharmaceutical sectors for companies of similar size and stage, such as Biogen Inc. or Vertex Pharmaceuticals Inc., which frequently use equity incentives to attract and retain board talent.

Corporate Governance

Related Party Transactions

• Grant of 21,500 stock options to James M. Frates, a director of Sage Therapeutics, Inc., as part of his non-employee director compensation.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director interests with shareholder value creation.

Next Steps

• Continued service of James M. Frates as a director until at least the vesting date (June 11, 2026, or prior to 2026 Annual Meeting).
• Potential exercise of stock options by James M. Frates after vesting and before expiration.

Key Dates

Recommendation

Keywords

Sage Therapeutics, SAGE, stock option, equity incentive plan, director compensation, Form 4, insider transaction, beneficial ownership